RECENT NEWS

Humans on a chip – the future for research and drug discovery

Humans on a chip – the future for research and drug discovery

Medicines Discovery Catapult, the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS), based at the University of Liverpool, and the National Centre for the Replacement Refinement & Reduction of Animals in Research (NC3Rs), combined forces recently to bring together experts from the field of organ-on-a-chip technology (OOAC) at the Sensor City in Liverpool.
Putting it all together, building the measurement uncertainty budget

Putting it all together, building the measurement uncertainty budget

The seventh and final article in the Pathology in Practice series by Stephen MacDonald on individual aspects of the assessment of uncertainty of measurement will provide an example of how to set, assess and review measurement uncertainty (MU) in any situation in the laboratory.
Exhibition showcase dedicated to the laboratory

Exhibition showcase dedicated to the laboratory

Lab Innovations returns to the NEC, Birmingham, on 31 October – 1 November 2018. Free-to-attend and supported by some of the UK’s top scientific institutions, Lab Innovations is the nation’s largest gathering of laboratory professionals, with almost a third more attendees in 2017. As well as an exhibition of products and services, visitors can also benefit from learning and business opportunities, with 98% recommending Lab Innovations as a ‘must attend’ event.
Sheffield Coroner’s Office adopts fingertip drug test

Sheffield Coroner’s Office adopts fingertip drug test

Mortuary staff in Sheffield are using a new fingertip-based drug screening system to carry out a simple, non-invasive drug test on the deceased at the city’s Medico-Legal Centre, when pathologists indicate it may be helpful. The test works by analysing sweat deposits that remain on the fingertips after death.
Biomarker test for high-grade prostate cancer could avoid need for biopsy

Biomarker test for high-grade prostate cancer could avoid need for biopsy

ProteoMediX has announced the results from a retrospective study that showed the correlation of its prostate cancer diagnosis test with cancer aggressiveness in patients scheduled for prostate biopsies. The study findings presented at the 2018 European Association of Urology (EAU) Congress in Copenhagen, Denmark, showed that the test has the potential to avoid a large number of biopsies.
Risk of spontaneous preterm birth assessed by point-of-care testing

Risk of spontaneous preterm birth assessed by point-of-care testing

Qiagen has received US regulatory approval for PartoSure, a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labour. Approval by the US Food and Drug Administration (FDA) follows successful uptake of the rapid test in more than 35 countries across Europe, the Middle East, Asia and Latin America.
Gene editing to improve red cell transfusion compatibility

Gene editing to improve red cell transfusion compatibility

Synthetic biologists at the University of Bristol have succeeded in generating laboratory-made red blood cells with rare blood group types that could one day be used to help patients who cannot be matched with donor blood.
Organisational changes strengthen push into molecular diagnostics

Organisational changes strengthen push into molecular diagnostics

Oxford Gene Technology (OGT) announced recently that Dr John Anson (pictured) has taken over as CEO from Dr Mike Evans, who has become a non-executive director of OGT’s board. In addition, as part of the company’s increasing focus on diagnostics following its acquisition by Sysmex, OGT has appointed Paul Kenny in a new regulatory position—EVP of Regulatory and Medical Affairs. This new appointment will equip the company to navigate the ever-evolving IVD regulatory landscape.
Diagnostic test to support malaria elimination

Diagnostic test to support malaria elimination

United Kingdom-based test developer Mologic and US-based PATH have entered an agreement to advance a new rapid diagnostic test to support treatment and elimination of Plasmodium vivax, or relapsing, malaria. More than 2.5 billion people worldwide are at risk of infection with P. vivax malaria, mainly in South East Asia and Latin America. P. vivax is especially difficult to eliminate because the parasite can lie dormant in the liver and re-emerge, causing periods of relapsing illness. With each relapse, patients become progressively sicker, and can continue to spread the disease through mosquitoes to other members of the community.
Rapid Diagnostics – Time is Relative

Rapid Diagnostics – Time is Relative

The British Society for Microbial Technology (BSMT) has an excellent programme for its annual scientific conference, to be held on Friday, 18 May at PHE Colindale. The focus will be on Rapid Diagnostics – Time is Relative, and the meeting is relevant for senior biomedical and clinical scientists, other scientists and medical microbiologists.
New diagnostic testing transforms Health Board in South Wales

New diagnostic testing transforms Health Board in South Wales

A year after becoming the first site in the UK to benefit from the latest development in diagnostic testing from Roche Diagnostics, a pathology service in South Wales has seen turnaround times and overall efficiency of its laboratory transformed.
Support for gene and cell therapy applications

Support for gene and cell therapy applications

Gyros Protein Technologies announced recently that Oxford BioMedica has invested in two Gyrolab xPlore systems. This is the first time the Gyrolab technology has been applied within the gene and cell therapy area.
Coeliac disease: boosting research efforts

Coeliac disease: boosting research efforts

The independent charity Coeliac UK has launched a research fund and accompanying fundraising appeal, which aims to raise £5 million to change the future for people with coeliac disease and gluten-related autoimmune conditions. It will boost research efforts into key areas identified and agreed by patients, carers and healthcare professionals.
Non-invasive liver profile testing

Non-invasive liver profile testing

Developed by scientists at the VIB University of Ghent, Belgium, the Glyco Liver Profile test from Helena Biosciences is the first of its kind delivering a comprehensive picture of chronic liver disease enabling clinicians to diagnose and monitor patients with hepatic inflammation, fibrosis and cirrhosis while providing a prognostic marker of hepatocellular carcinoma (HCC) risk.
Earlier clinical decision-making with POCT in emergency paediatrics

Earlier clinical decision-making with POCT in emergency paediatrics

In work recently undertaken and published as a case study by the Oxford Academic Health Science Network (AHSN), Horiba UK Medical’s Microsemi CRP point-of-care testing (POCT) analyser was found to enable more rapid clinical decision-making, saving time and reducing costs, in emergency paediatric units.
Measurement uncertainty: more budget topics

Measurement uncertainty: more budget topics

The sixth in this important series of articles by Stephen MacDonald on individual aspects of the assessment of uncertainty of measurement considers the impacts created when contributors are not measured in the same units. Coverage continues towards understanding the application of measurement uncertainty to laboratory assays.
Immunohistochemistry video training series

Immunohistochemistry video training series

Vector Laboratories has announced its new five-part video training series on immunohistochemistry (IHC). 'Become an IHC Expert (and Avoid Common Pitfalls)' is being released online, one segment per day. Access to the training series is free of charge, and topics covered include how to select reagents depending on experimental priorities, how to use ancillary reagents to improve results, how to optimise the protocol, and when to use advanced detection protocols.
Gene expression library

Gene expression library

Horizon Discovery has introduced Edit-R CRISPRa arrayed CRISPR RNA (crRNA) libraries, the latest addition to its CRISPR activation (CRISPRa) reagent platform from the recently acquired Dharmacon business. The new libraries offer a powerful tool for drug discovery, pathway analysis and disease progression studies.
Childhood arthritis: launch of a five-year study

Childhood arthritis: launch of a five-year study

Medical Research Council-funded scientists are beginning a five-year study of childhood arthritis and its linked eye inflammation, uveitis, with the aim of better understanding how to treat the complex condition, which affects one in 1000 under the age of 16 in the UK.
Investment in digital pathology platform unveiled

Investment in digital pathology platform unveiled

Driving down turnaround times (TATs), to enable more rapid diagnosis and treatment of patients, is the key philosophy of Source BioScience. As a leading provider of outsourced histopathology services to the NHS and private healthcare centres in the UK, Source BioScience has, after a detailed review of all other available alternatives in the digital marketplace, unveiled investment in a digital pathology platform from its preferred partner, Philips.

Upcoming Events

Update Course in Gynaecological Cytology

London Regional Cytology Training Centre, Level 6X, St Marks Building, Watford Road, Harrow HA1 3UJ
12-14 December 2018

Managing Cultural Differences in the Workplace

The Holiday Inn - Kensington Forum, 97 Cromwell Road, London SW7 4DN
21 January 2019

British Society for Haematology Paediatric Symposium

Royal College of Paediatrics and Child Health, 5-11 Theobalds Road, London WC1X 8SH
14 February 2019

Challenges in the clinical biochemistry laboratory and beyond

The Royal College of Pathologists
28 February 2019

British Society for Haematology 59th Annual Scientific Meeting

SEC Glasgow
1-3 April 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Dec 2018

Molecular diagnostics and LAMP technology

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.